Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2006 1
2007 3
2008 5
2009 1
2010 1
2011 2
2012 2
2013 2
2014 5
2015 4
2017 1
2018 1
2019 2
2020 1
2021 7
2022 7
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations.
Bobbili PJ, Ivanova J, Solit DB, Mettu NB, McCall SJ, Dhawan M, DerSarkissian M, Arondekar B, Chang J, Niyazov A, Lee J, Huq R, Green M, Turski M, Lam P, Muthukumar A, Guo T, Mohan M, Zhang A, Duh MS, Oh WK. Bobbili PJ, et al. Among authors: arondekar b. Clin Genitourin Cancer. 2024 Mar 23;22(3):102080. doi: 10.1016/j.clgc.2024.102080. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38653037
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Mahtani R, et al. Among authors: arondekar b. BMC Cancer. 2022 Dec 22;22(1):1343. doi: 10.1186/s12885-022-10325-9. BMC Cancer. 2022. PMID: 36550413 Free PMC article.
Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Mahtani R, et al. Among authors: arondekar b. Breast. 2022 Dec;66:236-244. doi: 10.1016/j.breast.2022.10.009. Epub 2022 Oct 18. Breast. 2022. PMID: 36368161 Free PMC article.
Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
Mahtani R, Niyazov A, Lewis K, Rider A, Massey L, Arondekar B, Lux MP. Mahtani R, et al. Among authors: arondekar b. Adv Ther. 2023 Jan;40(1):331-348. doi: 10.1007/s12325-022-02302-2. Epub 2022 Oct 28. Adv Ther. 2023. PMID: 36333567 Free PMC article.
47 results